Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) pioneers regenerative medicine solutions through its plant-based recombinant human collagen (rhCollagen) technology. This dedicated news hub provides investors and stakeholders with timely updates on clinical advancements, strategic partnerships, and product developments in 3D bioprinting, medical aesthetics, and tissue repair.
Access official press releases covering regulatory milestones, research breakthroughs, and commercial collaborations with industry leaders like AbbVie and Stratasys. Our curated collection includes updates on Vergenix™ wound care products, rhCollagen BioInk applications, and progress in regenerative breast implant development.
Discover comprehensive coverage of financial results, intellectual property expansions, and manufacturing scale-up initiatives. This resource serves as your primary source for tracking CollPlant's progress in addressing unmet needs across orthobiologics, advanced wound care, and organ manufacturing markets.
Bookmark this page for streamlined access to CLGN's latest developments in biocompatible medical solutions. Check regularly for updates on ESG initiatives, patent filings, and clinical trial outcomes that shape the company's position in the $3B+ regenerative medicine sector.
Stratasys (SSYS) and CollPlant (CLGN) have announced a joint development and commercialization agreement to focus on bioprinting solutions for regenerative breast implants, targeting a
CollPlant Biotechnologies (Nasdaq: CLGN) reported its financial results for the full year 2022, revealing a significant net loss of $16.9 million or $1.53 per share, compared to a profit of $237,000 in 2021. Revenue plummeted to $299,000, a decrease of $15.3 million year-over-year, largely due to a prior $14 million upfront payment from AbbVie. Despite these challenges, CollPlant is advancing its strategic collaboration with AbbVie in developing dermal fillers and is planning further studies for its 3D bioprinted breast implants, targeting a $2.6 billion market. The company ended 2022 with $29.7 million in cash and equivalents.
FAQ
What is the current stock price of Collplant Biotechnologies (CLGN)?
What is the market cap of Collplant Biotechnologies (CLGN)?
